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Abstract 
Background: Colorectal cancer (CRC) remains a major public concern. While conventional chemotherapeutic 
regimens have proved useful against advanced/metastatic diseases, progresses are to be made to effectively cure the 
large portion of patients not benefiting from these treatments. One direction to improve response rates is to develop 
chemosensitivity and resistance assays (CSRAs) efficiently assisting clinicians in treatment selection process, an already 
long preoccupation of oncologists and researchers. Several methods have been described to this day, none achieving 
yet sufficient reliability for recommended use in the clinical routine.
Methods: We led a pilot study on 19 metastatic CRC patients evaluating capacity of the Oncogramme, a standard‑
ized process using tumor ex vivo models, to provide chemosensitivity profiles and predict clinical outcome of patients 
receiving standard CRC chemotherapeutics. Oncogramme responses were categorized according to the method of 
percentiles to assess sensitivity, specificity and concordance.
Results: We report from a primary analysis a success rate of 97.4 %, a very good sensitivity (84.6 %), a below‑average 
specificity (33.3 %), along with a global agreement of 63.6 % and a concordance between Oncogramme results and 
patients’ responses (Kappa coefficient) of 0.193. A supplementary analysis, focusing on CRC patients with no treat‑
ment switch over a longer time course, demonstrated improvement in specificity and concordance.
Conclusions: Results establish feasibility and usefulness of the Oncogramme, prelude to a larger‑scale trial. Advan‑
tages and drawbacks of the procedure are discussed, as well as the place of CSRAs within the future arsenal of meth‑
ods available to clinicians to individualize treatments and improve patient prognosis.
Trial registration: ClinicalTrials.gov database, registration number: NCT02305368
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Background
Colorectal cancer (CRC) is a major public health con-
cern, being the third-most cancer diagnosed worldwide 
and the second-leading cause of cancer-related mortality 
in industrialized countries ([1]; GLOBOCAN data from 
the International Agency for Research on Cancer, avail-
able at http://globocan.iarc.fr/Pages/fact_sheets_cancer.
aspx, accessed December 14, 2015), where combination 
of lifestyle and environmental factors are suspected to be 
responsible for such prevalence [2], besides heritable fac-
tors [3]. Moreover, as CRC declares at a median age of 
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available at http://seer.cancer.gov, accessed December 
14, 2015), its occurrence is expected to continue rising in 
populations where life expectancy increases. Main treat-
ment for early stage malignancy is surgery. Later stage 
diseases or patients in palliative care are treated with 
chemotherapy and/or targeted therapy in neoadjuvant/
adjuvant settings, radiotherapy being additionally used 
for rectal cancer [3].
Several chemotherapeutic regimens are currently 
employed against advanced CRC. Most of them include: 
(1) the antimetabolite 5-fluorouracile (5-FU) or its pre-
cursors; (2) the thimidylate synthase inhibitor folinic 
acid (FA), enhancing the effects of 5-FU; (3) the topoi-
somerase inhibitor irinotecan; (4) the DNA-crosslinker 
oxaliplatin. 5-FU has been used for decades and still is 
a cornerstone for treatment of metastatic CRC, while 
irinotecan and oxaliplatin have been introduced for the 
last 15  years [4]. These molecules are used in combina-
tion doublet (5-FU and FA) or triplets (FOLFIRI: 5-FU, 
FA and irinotecan; FOLFOX: 5-FU, FA and oxaliplatin) 
for first- and second-line treatments, both triplets being 
equally effective [5]. These therapies are associated with 
known toxicities, whose severity depends on patients’ age 
or comorbidities and may worsen their overall condition, 
hence influencing therapeutic decisions.
A 2003–2009 US survey showed that metastatic CRC 
has a 5-year survival below 13 % [6]. However, advances 
in treatment have allowed significant amelioration in 
median overall survival (OS), now close to 24  months 
[7]. Such figures highlight the fact that prognosis can still 
be improved, either by developing more effective treat-
ments, or better targeting existing therapies, or a combi-
nation of both.
Clinicians have access to complementary information 
to help them selecting a curative regimen, comprising 
pathological and molecular data as well as clinical char-
acteristics of individuals. Yet, selection remains based 
on empirical decisions balancing therapeutic benefits 
and potential toxicity experienced by patients, and there 
is currently no efficient means of determining early the 
most appropriate chemotherapy. Inter- and intratumor 
heterogeneity, even within same histologic types [8], is 
mainly responsible for making responses to drugs highly 
unpredictable.
Because of such drawbacks, it appears that the “one-
size-fits-all” approach is no longer suitable. In that con-
text, a tool efficiently assisting clinicians in selecting 
drugs for a specific patient would be of high interest. 
This tool should provide data for improving response to 
treatments, i.e. ameliorate prognosis by suggesting better 
therapeutic options earlier in the disease, while avoiding 
multiple cycles of ineffective drugs with notable toxic-
ity. Also, anticancer treatments and patient care being 
increasingly expensive [9], a complementary advantage 
would be reduction of the economic burden linked to 
overall care.
Presently, several approaches have been devised to 
achieve such goal. One direction is to identify relations 
between expression of specific genes/sets of genes and 
sensitivity or resistance to anticancer molecules [10]. 
Another direction is the use of chemosensitivity assays.
Chemosensitivity assays, generally termed individual-
ized tumor response testing (ITRT) or chemotherapy 
sensitivity and resistance assays (CSRAs), have been 
developed for several decades [11], producing a dense 
literature that includes results from preclinical research, 
retrospective studies and assay-directed clinical trials on 
various types of cancer. Assay procedures look at differ-
ent endpoints [12–19], which all share the common fea-
ture of being measured on ex vivo models, either whole/
minced patient tissue samples, or primary cultures 
derived from these. In addition, most studies are directed 
toward advanced/metastatic/relapsed cancers, for which 
therapeutic options are limited, but also because such 
tumors provide larger quantities of material.
Usefulness and reliability of CSRAs have proven highly 
variable. The main reason put forward to explain this 
shortcoming is “the failure of such tests to identify clin-
ically-active drugs” [20] and thus really impact patient 
survival. As a consequence, in its latest update of guide-
lines regarding use of CSRAs, the American Society of 
Clinical Oncology (ASCO) still does not recommend 
such tests outside of the clinical trial setting, but main-
tains as a priority their continued evaluation because of 
their potential importance [21]. Nevertheless, chemosen-
sitivity assays are already commercially available in North 
America [22–24], Japan [25] and United Kingdom [26].
The company Oncomedics has developed several ex vivo 
primary culture cancer models. They are obtained thanks 
to the use of chemically-defined media, which allow tis-
sue preservation, dissociation and subsequent culture, 
while maintaining intrinsic heterogeneity of original 
tumor cell subpopulations. Hence, when transferred to 
an in-house fully-standardized methodology termed “the 
Oncogramme”, such models have appeared suitable to 
determine response profiles to chemotherapeutic agents 
on CRC [27], breast [28] and ovarian [29] cancers, enrich 
CRC cell lines in immature cells [30], and even predict 
sensitivity of breast cancer to targeted treatments [31].
Because of the demonstrated relevance of these mod-
els, we decided to complete a prospective pilot clinical 
trial aiming at evaluating (1) technical feasibility of the 
Oncogramme in a clinical context, and more importantly 
(2) its predictive effectiveness for a small cohort of stage-
IV CRC patients receiving currently approved chemo-
therapies as part of their treatment protocol. Beyond an 
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excellent success rate for effective patient profiling, we 
report from a 19-patient cohort a very good sensitivity 
but a below-average specificity, weakening concordance 
but still allowing a global agreement of 63.6 % (percent-
age of patients whose response to drugs was correctly 
predicted by the Oncogramme). Supplementary analysis, 
focusing on a subset of patients having received only one 
chemotherapeutic treatment for a longer time course, 
displayed improved specificity, agreement and concord-
ance. These results overall demonstrate practicability 
and usefulness of the Oncogramme, and indicate future 
directions for global enhancement of the method.
Methods
Patient selection
Only stage-IV colorectal cancer patients were recruited, 
because of feasibility of metastatic lesions follow-up. Cri-
teria for inclusion and exclusion of patients are presented 
in Additional file 1: Table S1.
Sample selection
Fresh stage-IV colorectal cancer specimens were anony-
mously obtained from non-objecting patients treated at 
the Centre Hospitalier Régional Universitaire (CHRU) 
Dupuytren (Limoges, France) from January 2011 till 
December 2012, and set to undergo primary tumor resec-
tion. Scientific and clinical significance of the study was 
validated by the Délégation à la Recherche Clinique et à 
l’Innovation (DRCI). Study protocol and case report form 
were approved by the Comité de Protection des Personnes 
(CPP) Sud-Ouest et Outre-Mer IV. Authorizations were 
obtained from the Comité Consultatif sur le Traitement 
de l’Information en Matière de Recherche dans le domaine 
de la Santé (CCTIRS) and the Commission Nationale 
Informatique et Libertés (CNIL).
Following surgical resection, primary lesions were 
histologically qualified by a pathologist through system-
atic analysis of sections facing site of sampling. If tumor 
was large enough to provide tissue for both diagnosis 
and Oncogramme purposes, a non-peripheral yet non-
necrotic portion (100–200  mm3) of each fresh, unfixed 
tissue was collected in OncoMiD-Via for colon conserva-
tion medium (Oncomedics) within 2 h of resection and 
stored at 4 °C for a maximum of 48 h. Site of invasion of 
colon/rectum wall was carefully preserved for diagnosis, 
and staging was determined according to TNM 7th edi-
tion staging system [32]. Remote lesions had to be meas-
urable according to response evaluation criteria in solid 
tumors (RECIST 1.1, described in [33]), and their evo-
lution following treatment was also assessed based on 
these criteria. Initial pre-surgery identification of meta-
static lesions was performed thanks to computed tomog-
raphy (CT), magnetic resonance imaging (MRI), and/or 
18F-fluorodeoxyglucose positron emission tomography-
computed tomography (FDG-PET-CT). Per-surgery 
observations completed identification in patients for 
whom metastases had not been previously discovered.
Sample processing and primary culture
Samples reserved in OncoMiD-Via for colon were trans-
ported according to UN3373 classification standards. 
Dissociation was performed with OncoMiD-Diss for 
colon dissociation kit (Oncomedics), involving mechani-
cal and chemical steps [27]. Cell viability was assessed by 
trypan blue exclusion assay (Sigma Aldrich). Cells were 
seeded at a density of 4–8.105 cells/mL in OncoMiD 
for colon serum-free, defined medium (Oncomedics), 
supplemented with 2.5  µg/mL amphotericin B (Sigma 
Aldrich) in EasyFlask, polystyrene Nunclon-treated cul-
ture dishes with filter caps (Nunc). Cultures were kept at 
37 °C in a humidified incubator (Binder CS 150) in a 95 % 
air 5  % CO2 atmosphere. Medium containing ampho-
tericin B was renewed after 5 days.
Chemotherapies
Stock solution of chemotherapies (all purchased from 
Sigma Aldrich) were prepared as follows: 5-fluorourac-
ile (5-FU) was diluted at 1 mg/mL in phosphate-buffered 
saline (PBS) 10  % dimethylsulfoxyde, while folinic acid 
(FA), irinotecan and oxaliplatin were diluted at 5 mg/mL 
in H2O.
Exposure to chemotherapies
After 7  days of culture, cells were collected and centri-
fuged for 10 min at 300 g, their viability was assessed with 
trypan blue, and 8-well lab-tek culture chambers (Nunc) 
were seeded. Each well received 5.104 live cells in final 
volume of 500 µL OncoMiD for colon. For one patient, 
a complete experiment included 4 conditions in mon-
oplicate: untreated; 5-FU and FA; FOLFIRI; FOLFOX. 
Chemotherapies were added at previously determined 
final concentrations [27]: 5-FU  =  25; FA  =  5; irinote-
can  =  100; oxaliplatin  =  150  µg/mL. Culture chamber 
was placed back in incubator for 72 h.
Cell viability/mortality labeling
Following exposure to treatments, cell viability was 
assessed through a fluorescent triple labeling. Briefly, 
cells were incubated for 45 min in PBS containing 4 µM 
acetomethoxy derivate of calcein and 0.1  µM ethidium 
homodimer-1 (LIVE/DEAD® Viability/Cytotoxicity kit, 
Life Technologies). They were then washed with PBS 
and fixed in PBS 4  % formaldehyde (Sigma Aldrich) for 
10 min. After a wash with PBS, total cell population was 
labeled through incubation in H2O containing 0.5 µg/mL 
4′,6-diamidino-2-phenylindole (DAPI; Sigma Aldrich). 
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Cells were then washed 3 times in PBS, once in H2O, and 
dried. Finally, slides were mounted with glycerol/gelatin 
mounting medium (Sigma Aldrich) and stored at −20 °C 
until readout.
Cytotoxicity analysis
Cells were observed with a fluorescence microscope 
(Nikon). Multi-channel pictures randomly covering the 
surface of each well were taken using NIS-Elements BR 
3.1 software (Nikon). Variable number of pictures were 
taken for each patient, to provide sufficient number of 
cells (at least 1000) for accurate results. Live, dead and 
overall cell populations were counted and percentage of 
dead cells was determined for each condition. Finally, 
for each patient, ratios of death percentages for treated 
cells to death percentages for untreated cells were com-
puted. Whole endpoint analysis was solely performed by 
one person (CBMP). Results were not communicated to 
clinicians.
Results categorization and statistical analysis
After each clinical evaluation (variable time interval, 
usually 2–4  months), patients were categorized into 
responders (complete or partial response, stable dis-
ease) and non-responders (progressive disease) to 
treatments according to RECIST 1.1. Results were not 
communicated to Oncogramme reader until end of 
study. Oncogramme results were categorized accord-
ing to the method of percentiles [34]: patients highly 
sensitive to treatments were those for which ratios were 
above 75th percentile; intermediate sensitive patients 
included patients for which ratios were between 25th 
and 75th percentiles; resistant patients included patients 
for which ratios were below 25th percentile. After data 
verification, database was frozen and statistical analysis 
was computed. All quantitative variables were described 
by mean  ±  standard deviation, minimum, maximum, 
median and interquartile range. Qualitative variables 
were described by frequencies and percentages. Capacity 
for the Oncogramme to identify responders as sensitive 
ex  vivo to the chemotherapy they actually received was 
defined as sensitivity. Capacity for the Oncogramme to 
identify non-responders as resistant ex vivo to the chem-
otherapy they actually received was defined as specificity. 
These measures of validity were estimated using a con-
tingency table crossing results observed on patients and 
Oncogramme results. Their 95  % confidence intervals 
(CIs) were calculated with the exact method. To quan-
tify concordance between Oncogramme results following 
categorization and results observed on patients, Kappa 
coefficient, ranging from −1 to 1, was also estimated with 
a 95 % confidence interval. For its interpretation, catego-
ries from Landis and Koch [35] were used.
Quality control
Reporting of clinical data, deviations from initial pro-
tocol, assay results and overall writing of manuscript 
followed STAndards for the Reporting of Diagnostic 
accuracy studies (STARD, http://www.stard-statement.
org/).
Results
Diagram presenting the inclusion process appears in 
Fig. 1a. Initially, 64 patients were enrolled, with 63 sam-
ples properly transmitted from surgery room to Onco-
medics’ facility. Stage-IV colon carcinoma was diagnosed 
for 26 patients, 6 of which did not actually receive any 
chemotherapy. Finally, 1 patient received pre-surgery 
chemotherapy only, while 19 patients received either 
pre- and/or per- and post- (3 patients) or only post-sur-
gery (16 patients) chemotherapy. These 19 patients were 
finally included in the study.
Flowchart summarizing the whole Oncogramme pro-
cedure is presented in Fig.  1b. The only deviation from 
protocol occurred for 2 patients (n° 12 and 18), whose 
samples were processed 3  days after surgery instead of 
the 2  days initially planned because of improper trans-
mission of information between pathology laboratory 
and Oncomedics. Nevertheless, it did not impair comple-
tion of procedure, quality of cultures, and gathering of 
results for these individuals.
Table 1 presents main characteristics of the 19 included 
patients. Median age was 69 with an interquartile range 
of (62; 79) (mean =  65, range =  37–82), and an almost 
equal repartition of individuals according to sex (9 
males, 10 females) was observed. Body mass index (BMI) 
showed the majority (52.6 %) of patients presented a nor-
mal range weight, while 10.5  % were considered under-
weight (BMI < 18.5), 21.1 % overweight (25 < BMI < 30), 
and 15.8 % obese (BMI > 30). American Society of Anes-
thesiologists (ASA) physical status score was used to 
assess fitness of patients before surgery: it indicated a 
severe systemic disease for 42.1  % patients (score =  3). 
Both indexes suggested potential preclusion of certain 
chemotherapeutic regimens for patients at risk. Localiza-
tion of primitive lesions spanned all colon segments (left/
descending colon: 42.1  %; sigmoid: 21  %; right/ascend-
ing colon: 31.6  %) and rectum (5.3  %). Metastases were 
identified pre-surgery in 57.9 % cases, while per-surgery 
observations completed identification of remote lesions.
Table  2 presents chemotherapy regimens followed by 
all patients, as well as their responses to treatment after 
each evaluation. For first cures, 31.6 % patients received 
5-FU with or without FA, 10.5 % received FOLFIRI, and 
57.9  % received FOLFOX. Twenty-one percent patients 
received consecutive lines of treatments involving 2 or 
3 chemotherapies. Twenty-one percent patients died 
Page 5 of 12Bounaix Morand du Puch et al. J Transl Med  (2016) 14:10 
before the end of study, all of them because of disease 
progression. Minimal follow-up time was 13  months 
for patients who did not die before study completion. 
Patients were subsequently categorized into responders 
and non-responders. It is noteworthy that 8 patients were 
administered angiogenesis inhibitor bevacizumab during 
the course of their treatment, six of which as soon as first 
cure. Since our ex vivo two-dimensional model is devoid 
of microenvironment and vascular network, this anti-
body could not be tested through such configuration of 
the Oncogramme. However, as an anti-angiogenic agent, 
it was shown not to have an effect on response rates and 
survival by itself, but rather to reinforce the action of 
chemotherapies [36]: this is why we decided to include 
patients that received this molecule. Also, 1 wild-type 
KRAS patient received panitumumab, which targets EGF 
receptor to inhibit cell proliferation. In our study, admin-
istration of this antibody was non-concomitant with any 
chemotherapy, thereby not interfering with comparison 
of patient outcome following a 5-FU first line.
Contamination-free primary cultures were obtained 
in 100  % cases. Only sample of patient 06 did not pro-
vide enough cells to test all 4 planned experimental 
conditions: in addition to untreated well, cells were 
only exposed to 5-FU and FA, while the patient actually 
received FOLFIRI. Hence, a success rate of 74/76 experi-
mental conditions (97.4  %) was obtained. Comparison 
between assay results and clinical outcome was possible 
for 18/19 patients (94.7 %) and, since 4 patients received 
two or more lines of different treatments, we were finally 
able to compare clinical outcome with ex  vivo assay 
results in 22 cases.
Mortality of untreated cells after 10  days of culture 
was extremely variable from patient to patient (range 
8.2–30.9 % dead cells; median: 18.1 %). In order to bet-
ter compare results among subjects, we chose to report 
chemotherapy responses normalized to references 
obtained on untreated cells. Ranges of ratio for each 
chemotherapeutic condition are presented in Table  3. 
As results were not normally distributed, median was 
used. Twenty-fifth and 75th percentiles were computed. 
Because of the use of monoplicates, no coefficient of vari-
ation was determined.
Table  4 presents ex  vivo results for each patient fol-
lowing their categorization according to the method of 
percentiles. Highly and intermediate sensitive patients 
were gathered in the “sensitive” category. Table 5 matches 
clinical responses with Oncogramme profiles. This table 
allowed determining Oncogramme sensitivity at 84.6  % 
[11/13, 95 % confidence interval (CI) (54.5; 98.1)]. Con-
secutively, specificity was determined at 33.3 % [3/9, 95 % 
Fig. 1 a Overview of patient selection process in the pilot trial, from 
initial recruitment to final inclusion. From the 64 individuals originally 
recruited, exclusion and inclusion criteria allowed to finally select 19 
patients with stage‑IV CRC, pre‑ + post‑ or post‑surgery treatment, 
RECIST 1.1‑measurable lesions and consistent clinical follow‑up. b 
Overview of the Oncogramme experimental procedure, from surgery 
to readout. Viable samples were recovered and processed to obtain 
primary cultures that were subsequently utilized for realization of 
the Oncogramme by exposure to chemotherapeutic drugs and cell 
death analysis. Whole time course was inferior to 2 weeks
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CI (7.5; 70.1)]. Oncogramme results were in accordance 
with patient outcome in 14/22 (63.6  %) cases. Kappa 
coefficient was measured at 0.193 [95  % CI (−0.196; 
0.582)], indicating a real concordance between ex  vivo 
and clinical results of 19.3 % non-attributable to random-
ness (very weak). 
To investigate predictive capacities of the Oncogramme 
on longer course treatments and on tumors whose sen-
sitivity profile to other chemotherapies could not be 
altered by a first line regimen, a supplementary analysis 
was performed only on those patients who received at 
Table 2 Treatments and clinical responses of advanced CRC patients included in the pilot trial
Chemotherapy regimens received by each patient during the course of their treatment, and ensuing clinical outcome (disease progression, stabilization, partial or 
complete response) determined through three consecutive evaluations. Survival time at completion of study is also provided
a Patient died before end of study as a result of CRC progression
b Received pre- and or per-surgery chemotherapy
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04a 4 C FOLFOX + Bevacizumab
Partial response





05b 6 C FOLFOX + Bevacizumab
Stable disease





06b 4 C FOLFIRI + Bevacizumab
Stable disease



















09a,b 4 C FOLFOX
Disease progression



















12 4 C FOLFIRI + Bevacizumab
Stable disease












14 8 C FOLFOX
Stable disease





15 4 C FOLFOX + Bevacizumab
Partial response












17 7 C FOLFOX + Bevacizumab
Disease progression





18 4 C FOLFOX
Partial response












Table 3 Main Oncogramme results following  determina-
tion of cytotoxicity on individual primary cultures
Figures presented are derived from ratios (% dead cells for treated condition/ % 
dead cells for untreated condition) obtained for the 19 advanced CRC patients 
included in the pilot trial. Mean and median values, as well as standard deviation 









5‑FU + FA 1.343 0.895 2.102 1.029 1.701
FOLFIRI 1.633 0.788 2.883 1.186 1.965
FOLFOX 1.787 1.147 3.613 1.579 2.090
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least first and second cures identical in their chemother-
apy composition (no treatment switch after first evalua-
tion). Thirteen patients were isolated, whose responses 
to treatments were compared to Oncogramme results 
(Table 4, ’’a’’ labelled patients). For that subgroup, sensi-
tivity was 70.0 % [7/10, 95 % CI (34.75; 93.33)], specific-
ity was 66.7 % [2/3, 95 % CI (9.43; 99.16)], and agreement 
between test results and patient outcome was visible in 
9/13 (69.2  %) cases. Kappa coefficient was measured at 
0.2973 [95 % CI (−0.2184; 0.8130)], indicating a real con-
cordance between ex  vivo and clinical results of 29.7  % 
non-attributable to randomness (weak), an improve-
ment from the primary analysis. Additionally, identical 
sensitivity and specificity were obtained when 25th and 
75th percentiles were re-computed using results obtained 
for these sole 13 patients, and a similar conclusion was 
drawn for real concordance (data not shown).
Additional file 2: Figure S1 presents examples of Onco-
gramme profiles for 4 patients, illustrating the heteroge-
neity of responses from patient to patient and from drug 
to drug.
Discussion
Because of lack of recommendation from authorities, 
there is currently no gold-standard for CSRAs. Also, as 
methods largely differ in ex  vivo models (histoculture, 
two-dimensional primary cultures, spheroids) as well as 
endpoints, it is difficult to closely compare them [37–42]. 
Nevertheless, our STARD-described pilot study dem-
onstrated technical advantages for the Oncogramme, 
owing to its original design and full standardization. 
First, necessary amount of specimen was small enough 
so that both complete diagnosis and Oncogramme pro-
cedure were possible. Then, use of proper decontamina-
tion procedure resulted in contamination-free primary 
cultures for all cases. Contaminations are a notable hur-
dle in CSRAs, especially those involving CRC samples. 
Table 4 Oncogramme results for  the 19 advanced CRC 
patients included in the pilot trial
Results were categorized according to percentile thresholds (R = resistant < 25th 
percentile < I = intermediate sensitive < 75th percentile < S = sensitive; 
N/D = not determined). Oncogramme results for treatments that were actually 
given to patients are underlined
a Indicates the 13 patients selected for the supplementary analysis, which were 
those who received equivalent chemotherapeutic treatments over the course of 
at least two evaluations
Subject ID Treatment
5-FU + FA FOLFIRI FOLFOX
01 S S S
02a S S I
03 S S S
04a R I I
05a I R R
06 I N/D N/D
07a S I I
08a I I I
09 R S S
10a I R S
11 I R I
12a I I I
13a S I I
14 I I S
15a I R R
16a I R R
17a I I R
18a R S I
19a R I I
Table 5 Correlation table matching patient responses with results of the Oncogramme assay (principal analysis)
                                                 









Sensitivity 11/13 = 84.6%
Specificity 3/9 = 33.3%
Advanced CRC patient responses (responder or non-responder to treatment) were correlated with results of the Oncogramme assay (sensitive or resistant) to 
identify true positives (patients termed as sensitive and that actually responded to treatment) and true negatives (patients termed as resistant and that actually did 
not respond to treatment). True positives and true negatives are highlighted in grey. Sensitivity (percentage of true positives) and specificity (percentage of true 
negatives) are also given
Page 9 of 12Bounaix Morand du Puch et al. J Transl Med  (2016) 14:10 
They may account for a failure rate >10 % [40], which is 
not acceptable because of clinical importance of patients’ 
samples.
It is noteworthy that most procedures previously 
described were performed on fragments or cells that 
either did not undergo a primary culture step or, when 
cultured, were placed in serum-containing media. Pro-
cess for the Oncogramme includes a non-passaged 
two-dimensional primary culture step. Downsides of 
primary culture include difficulties to avoid fibroblast 
contamination, loss of tumor architecture and cell–cell 
interactions, the two latter potentially being critical 
elements [38, 41]. Also, culture medium appears to 
be a decisive factor, since it must be able to preserve 
heterogeneity of tumor characteristics while allowing 
cell analysis through an easily manageable assay. To 
counter these disadvantages, we have designed defined 
medium OncoMiD for colon, providing a permis-
sive environment for tumor cells while compromising 
survival of fibroblasts [27]. Overall, our primary cul-
ture conditions are appropriate for: (1) favoring tumor 
cell maintenance; (2) avoiding clonal expansion of 
rapidly dividing tumor cells, thus preserving sample 
heterogeneity; (3) eliminating unwanted cell subpopu-
lations. Use of this medium resulted in 100 % success 
in primary culture, and comparison between patient 
response and assay results was possible in all but one 
case, a higher figure than previous reports [40, 41]. 
Ensuing increase in timeframe is not detrimental to 
patients, since first-line chemotherapy regimen is usu-
ally not started before several days or weeks after sur-
gery [43].
One of the main drawbacks of several approaches is 
their capacity to detect only actively proliferating cells, 
while not appraising programmed cell death consecu-
tive to drug treatment [20]. This is notably the case for 
clonogenic assays, which display moderate sensitivity 
[44]. Such tests usually fail at predicting clinical outcome. 
Our endpoint, indistinguishably assessing both metabolic 
capacity and membrane integrity, allows targeting all cells 
within the primary culture, regardless of proliferative/
quiescent state and death pathway. Potentially dormant 
cell subpopulations (reversibly non-dividing, in G0 phase) 
are hence visible. Also, MTT-based assays tend to lack 
sensitivity because of their optical density-based end-
point. The Oncogramme, relying on direct cell count, dis-
plays higher sensitivity, though currently at the expense 
of a longer analysis time than plate readers. This issue 
should be worked out for future studies. Also, absence of 
replicates prevented us to improve level of confidence of 
results: this will be reinforced in next studies by scaling 
down the protocol to allow performing replicates but also 
working on smaller samples.
CSRAs such as the Oncogramme aim at improving 
clinical response to first-line treatments, since any failing 
line decreases chances of effective cure. Average response 
rates observed in studies involving more than 100 meta-
static CRC patients and published in the last 15 years, for 
the 3 regimens employed here or their analogous, utilized 
as first-lines, were recently gathered [45]. Compiled fig-
ures are: 5-FU and folinic acid = 21.8 % ± 7.1 respond-
ers; 5-FU and folinic acid and irinotecan = 40.8 % ± 10.7; 
5-FU and folinic acid and oxaliplatin  =  46.4  %  ±  7.7. 
This confirms a large portion of CRC patients empiri-
cally treated with current standards-of-care ultimately 
do not respond to administered therapies. Prospective 
studies also evaluated the predictive capacity of CSRAs, 
but recent reviews compiling up-to-date results for sev-
eral pathologies are lacking [46]. Besides feasibility of 
the overall procedure in the clinical setting, primary goal 
of our pilot study was to determine whether the Onco-
gramme was capable of predicting objective response of 
stage-IV CRC patients to drugs currently in use. Despite 
a very low concordance (0.193), at least partly due to 
small size of the cohort, we achieved through the princi-
pal analysis a very good sensitivity [84.6 %, 95 % CI (54.5; 
98.1)], demonstrating a propensity to identify patients 
sensitive to drugs or combinations (responders). On the 
other side, non-responding patients represented 60  % 
(3/5) of negative assay results. However, below-average 
specificity [33.3  %, 95  % CI (7.5; 70.1)] was obtained, 
meaning rate of false-positives was superior to that of 
true-negatives. When selecting for a supplementary 
analysis patients that received only a single type of regi-
men over the course of first, second and sometimes third 
cures, the Oncogramme was able to detect responders in 
70 % cases and non-responders in 66.7 % cases. Despite 
being obtained on a low number of patients (n  =  13), 
these figures suggest the test may be effective at predict-
ing a patient response to a specific treatment (1) on a 
longer time-course (at least two evaluations); (2) when we 
avoid comparison between ex  vivo chemosensitivity of 
naive tumor cells and in situ responses of primary and/or 
distant lesions potentially affected by previous rounds of 
chemotherapies, as mechanisms of acquired cross-resist-
ances are not fully understood yet [47]. Our approach 
still allowed an acceptable sensitivity while reducing the 
risk of using drugs that will not be efficient. These predic-
tivity indicators clearly need to be reinforced on a larger 
cohort, where inclusion criteria will be adapted so as to 
select patients that received a particular treatment for a 
sufficiently long period of time to more precisely define 
the resistance/sensitivity limit.
As previously pointed out, the Oncogramme and all 
other CSRAs do not distinguish between cell subpopu-
lations making up the tumor ex  vivo model. Responses 
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provided by these tests are based upon global behavior 
of all cells when exposed to drugs: a generally respon-
sive tumor tissue can thus translate into a test result 
categorizing it as “sensitive”, while cancer stem cells, 
thought to be responsible for neoplastic resurgence and 
resistance to further treatment [48], will not be identi-
fied. This might explain the high patient death rate 
associated with false-positives in our principal analysis: 
indeed, among patients with false-positive Oncogramme 
responses (individuals 01, 03, 08 and 09), 3 eventu-
ally died of their disease. In addition, it is important to 
notice that in vitro/ex vivo responses are generally more 
exacerbated than in  vivo responses. This explains why 
numerous published works are actually more accurate 
at predicting resistance than sensitivity to drugs [38, 
41], a downside that has attracted criticism from the 
ASCO. Compared to whole organisms [20], and despite 
their relevance [49], in  vitro/ex vivo systems lack sur-
rounding tissues and microenvironment that regulate 
drug delivery and tumor/cell behavior and ultimately 
modify patient response. Tumor ex vivo reconstruction 
by assembling its components in co-culture systems may 
help overcome this hurdle, but such solution appears 
difficult to apply to the clinical setting. Development of 
a more relevant model, thanks to adequate sample pro-
cessing and culture conditions applicable to routine use, 
such as those included in the Oncogramme procedure, 
would be an equally elegant solution. Another important 
issue that should be considered for future developments 
of all CSRAs regards the representativeness of the work-
ing samples: they should encompass all characteristics 
of a patient’s own pathology, since variable cell death 
rates may be observed in superficial and deep parts of 
CRC tissue [39] while primary CRC tumor makeup, and 
thereby chemoresponses, may significantly differ from 
that of distant metastases [50].
Molecular approaches measuring the expression of 
markers potentially predictive of response to drugs are 
also widely considered for personalized medicine [51]. 
Up to now, however, CSRAs have proved to perform 
better in predicting clinical response to treatments 
in direct comparison studies [42, 52]. To maximize 
response rates, but also to understand mechanisms 
underlying intrinsic resistances and neoplastic resur-
gence, a synergistic framework combining CSRAs with 
relevant gene status studies could be envisioned [10, 
47]. In addition, the Oncogramme appears suitable for 
evaluation of targeted therapies [31] as well as experi-
mental molecules, cross-resistance drugs and synergis-
tic/additive effects. Only in such context of accumulated 
evidence will the Oncogramme and other CSRAs best 
support clinicians in their decision process, increasing 
drugs’ therapeutic index and improving patients’ quality 
of life. A recent observational study showed physicians 
are actually willing to use results of CSRAs when availa-
ble, and adapt their treatment protocol accordingly [53]: 
this establishes that potential role of such assistance and 
its diffusion through the medical community are not 
negligible.
Clinical feasibility of the fully-standardized Onco-
gramme was demonstrated on more than 60 patients. 
Despite a still weak concordance, mostly due to a low 
specificity that should be improved through more strin-
gent patient selection criteria, a good agreement with 
clinical observations was reached. Particularly, the very 
good sensitivity shows that the Oncogramme profiles 
may be employed by clinicians with a positive-only out-
come. It is now necessary to strengthen these preliminary 
results through a larger scale, randomized multicen-
tric prospective trial that will compare performances of 
Oncogramme-directed treatments and empirical, phy-
sician-directed treatments on CRC tumors. Such study 
will also help adjusting sensitive/resistant limits for each 
chemotherapy or combinations.
Conclusions
The goal of CSRAs is to assist clinicians in selecting the 
most appropriate treatment for a cancer patient by pro-
viding additional data regarding the chemosensitivity/-
resistance capacities of a her/his tumor. The 
fully-standardized method of the Oncogramme, applied 
to a small cohort of metastatic CRC patients, was able to 
identify with an excellent success rate and a very good 
sensitivity those who respond to conventional chemo-
therapeutic treatments. Specificity was below aver-
age, denoting a weakness of the method at pointing out 
resistances. However, we also showed that more strin-
gent selection criteria (longer follow-up of patients with 
no treatment switch) may help to drastically enhance 
this latter indicator, thereby ameliorating the global 
method efficiency. Despite the fact that our data need to 
be strengthened through a larger study, improvement of 
clinical response rates for standards-of-care appears pos-
sible through the Oncogramme.
Additional files
Additional file 1: Table S1. Criteria for inclusion and exclusion of CRC 
patients used in the Oncogramme pilot trial.
Additional file 2: Figure S1. Oncogramme profiles for 4 metastatic CRC 
patients included in the study. These profiles illustrate the heterogene‑
ity of responses that occur from patient to patient, and for the three 
administered therapies. Bold dotted vertical line indicates on each graph 
the positivity threshold: an Oncogramme result indicative of resistance 
to the considered treatment is materialized by a red column extending 
to the left of threshold, an Oncogramme result indicative of sensitivity is 
materialized by a blue column extending to the right of threshold.
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